Swiss drug major Roche Holding AG (RHHBY) announced Tuesday that EMBARK trial of Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy or DMD failed to reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints.